ArticleWorld journal of surgical oncology2026
Omission of completion axillary dissection in clinically node-negative breast cancer with 1-2 metastatic sentinel lymph nodes.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe SENOMAC trial demonstrated that omitting completion axillary lymph node dissection (ALND) is safe in patients with clinically node-negative (cN0) T1, T2, or T3 breast cancer with 1-2 sentinel-node macrometastases. However, its applicability to populations with higher mastectomy rates, such as in China, remains unclear. This study evaluated the safety and efficacy of omitting completion ALND in cN0 T1-T2 breast cancer patients who underwent sentinel lymph node biopsy (SLNB) with 1-2 SLN macrometastases in a Chinese cohort.
methodsThis single-center retrospective study included 202 patients diagnosed between January 1, 2017, and December 31, 2023, who underwent SLNB at our institute. Patients were divided into SLNB-only (n = 93) and completion ALND (n = 109) groups. Baseline characteristics were compared using chi-square or t-tests; survival outcomes and complications via Kaplan-Meier analysis, log-rank tests, and Cox proportional-hazards regression.
resultsMedian follow-up was 58 months (range = 3-103). No significant differences were found in 5-year recurrence-free survival (95.7%, vs. 94.5%, P = 0.96) and overall survival (OS) (97.8%, vs. 97.2%, P = 0.84) between the SLNB-only and completion ALND groups. The incidence of lymphedema, assessed by combined subjective and objective criteria, was significantly lower in the SLNB-only group than in the completion ALND group (4.3%, vs. 12.8%, P = 0.03). Hormone-receptor-positive status was an independent prognostic factor for OS (hazard ratio = 0.04, 95% confidence interval 0.004-0.46, P = 0.01].
conclusionIn this retrospective cohort, omission of completion ALND was not associated with a statistically significant difference in 5-year RFS or OS compared with completion ALND, while lymphedema incidence was significantly lower. These findings suggest that omitting ALND may be feasible in selected patients with cN0 T1-T2 breast cancer and 1-2 SLN macrometastases. However, given the study's limitations, future larger, prospective, randomized, and multicenter studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.